Rajasthan Medical Services Corporation Limited

Gandhi Block, SwasthyaBhawan, Tilak Marg, C-Scheme, Jaipur-302005 (Raj.)
Phone No: 0141-2228066 ,2228064 Fax No. 0141-2228065Website: http://rmsc.health.rajasthan.gov.in
CIN:U24232RJ2011SGC035067 E_mail :edprocurement@gmail.com, andrmsc@nic.in

Ref. No.:- F.02(270)/RMSCL/PROCUREMENT/DRUG/NIB-12/2019/1041 Dated:-07.10.2019

Corrigendum – II

Subject:-Amendments in BOQ/ technical specification/Packing Unit/Quantity

Ref.:- Prebid meeting dated 26.09.2019 and NIB No. F.02(270)/RMSCL/PROCUREMENT /DRUG/NIB-12/2019/1027 Dated:-18.09.2019 (Technical bid opening due on dated – 10.10.2019)

<table>
<tr><th>S. No</th><th>Existing condition / technical specification/Packing Unit/Quantity (clause no.)</th><th>Amended condition / technical specification/ Packing Unit/Quantity/Shelf Life/Date Extension (clause no.).</th></tr>
<tr><td>1.</td><td>Date of submission for E-bids reference no F.02(270)/RMSCL/PROCUREMENT /DRUG/NIB-12/2019/1027 Dated:-18.09.2019 is 6.00 PM of 09.10.2019
<table><tr><td>Last date and time of submission of online bids</td><td>09.10.2019 at 6.00 PM</td></tr><tr><td>Date and time of opening of Online technical bids</td><td>10.10.2019 at 11.00 AM</td></tr><tr><td>EMD, Tender fees, RISL fees through challan</td><td>09.10.2019 at 6.00 PM</td></tr><tr><td>EMD, Tender fees, RISL fees Physically</td><td>09.10.2019 at 6.00 PM</td></tr></table></td><td>Date Extended for submission of E-bids reference F.02(270)/RMSCL/PROCUREMENT /DRUG/NIB-12/2019/1027 Dated:-18.09.2019 is 6.00 PM of 14.10.2019
<table><tr><td>Last date and time of submission of online bids</td><td>14.10.2019 at 6.00 PM</td></tr><tr><td>Date and time of opening of Online technical bids</td><td>15.10.2019 at 11.00 AM</td></tr><tr><td>EMD, Tender fees, RISL fees through challan</td><td>14.10.2019 at 6.00 PM</td></tr><tr><td>EMD, Tender fees, RISL fees Physically</td><td>14.10.2019 at 6.00 PM</td></tr></table></td></tr>
<tr><td>2.</td><td>Annexure – VIII (List of Drugs with Specifications) and BoQ
<table><tr><th>Code No.</th><th>Name of item with specification</th></tr><tr><td>169</td><td>Desferrioxamine Injection IP 500 mg / Vial (For I.M. Inj and I.V., S.C. Infusion)</td></tr><tr><td>616</td><td>Formoterol Fumerate & Budesonide Powder For Inhalation IP 6 mcg + 200 mcg</td></tr></table></td><td>Annexure – VIII Item with code no 169 and 616 are deleted from Bid.
(Total Drugs in Bid 67)</td></tr>
<tr><td>3.</td><td>Clause 2(c) ELIGIBILITY CRITERIA
Clause 5 (i) (j) TECHNICAL BID
Annexure-XV Ref. Clause No. 2 (c)
<table><tr><th>Code No.</th><th>Name of item with specification</th></tr><tr><td>NE16</td><td>Dual Rapid Test kit for HIV & Syphilis</td></tr></table></td><td>Clause 2(c) ELIGIBILITY CRITERIA
Clause 5 (i) (j) TECHNICAL BID
Annexure-XV Ref. Clause No. 2 (c)
<table><tr><th>Code No.</th><th>Relaxation in Condition of Market Standing Certificate and Performance Statement</th></tr><tr><td>*NE16</td><td>1. Firm has to submit Market Standing Certificate of Dual Rapid Test kit for HIV & Syphilis for 6 months and Performance Statement of at least one batch in financial year 2018-19 or 2019-20.
2. Firm has to submit 3 year market standing for similar type of test kits.</td></tr></table>*However, for all above items, the firm has to submit with bid, the product permission (from the Licensing Authority) same as per bid specifications.</td></tr>
</table>

<table>
<tr><th>S. No</th><th>Existing condition / technical specification/Packing Unit/Quantity (clause no.)</th><th>Amended condition / technical specification/ Packing Unit/Quantity/Shelf Life/Date Extension (clause no.).</th></tr>
<tr><td>4.</td><td>Clause 5(l) TECHNICAL BID
WHO-GMP (WHO – Good manufacturing practices Certificate) Certificate issued by the Licensing Authority. The WHO-GMP certificate must not be older than one year from the due date of Bid submission in the case where validity is not mentioned in the certificate. The WHO-GMP certificate of all the manufacturing plants, of which products have been quoted, should be submitted. The Bidder shall also furnish an undertaking in the format given in Annexure-VII point no.8 declaring that the Bidder complies with the requirements of WHO-GMP. The Importer should produce WHO- GMP /COPP of the manufacturing firm or a certificate which is at par with WHO-GMP issued by exporting countries like US-FDA approval, etc. In the case of imported drugs, labels and product literature of all quoted products must be submitted.</td><td>Clause 5(l) TECHNICAL BID
In the existing condition of WHO-GMP in the clause, it is relaxed to WHO-GMP/GMP/QMS Certificate for below mentioned item codes :-<table><tr><th>Code No.</th><th>Name of item with specification</th></tr><tr><td>NE16</td><td>Dual Rapid Test kit for HIV & Syphilis</td></tr></table>WHO-GMP/GMP (Good manufacturing practices Certificate)/QMS Certificate issued by the competent authority. The WHO-GMP/GMP/QMS Certificate must not be older than one year from the due date of Bid submission in the case where validity is not mentioned in the certificate. The WHO-GMP/GMP/QMS Certificate of all the manufacturing plants, of which products have been quoted, should be submitted. The Bidder shall also furnish an undertaking in the format given in Annexure-VII point no.8 declaring that the Bidder complies with the requirements of WHO-GMP/GMP/QMS Certificate. The Importer should produce WHO- GMP /COPP of the manufacturing firm or a certificate which is at par with WHO-GMP issued by exporting countries like US- FDA approval, etc. In the case of imported drugs, labels and product literature of all quoted products must be submitted.</td></tr>
<tr><td>5.</td><td>Annexure – VIII (List of Drugs with Specifications) and BoQ<table><tr><th>Code No.</th><th>Name of item with specification</th><th>Minimum labelled Shelf Life (In Months)</th></tr><tr><td>128</td><td>Primaquine Tablets IP 2.5 mg</td><td>24</td></tr></table></td><td>Annexure – VIII (List of Drugs with Specifications) and BoQ<table><tr><th>Code No.</th><th>Name of item with specification</th><th>Minimum labelled Shelf Life (In Months)</th></tr><tr><td>128</td><td>Primaquine Tablets IP 2.5 mg</td><td>18</td></tr></table></td></tr>
<tr><td>6.</td><td>Annexure – VIII (List of Drugs with Specifications) and BoQ<table><tr><th>Code No.</th><th>Name of item with specification</th><th>Packing Unit</th></tr><tr><td>128</td><td>Primaquine Tablets IP 2.5 mg</td><td>10 x 10 Tab Strip/Blister</td></tr></table></td><td>Annexure – VIII (List of Drugs with Specifications) and BoQ<table><tr><th>Code No.</th><th>Name of item with specification</th><th>Packing Unit</th></tr><tr><td>128</td><td>Primaquine Tablets IP 2.5 mg</td><td>10x10 Tab Strip/Blister or 10 x 7 Tab Strip/Blister</td></tr></table></td></tr>
</table>

Note:-

- **It may be noted that if any further amendments are issued then a corrigendum will be published and informed.**
- **Rest of the terms and conditions will remain the same.**

Executive Director (Proc.)
RMSCL